These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17724362)

  • 1. Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone.
    Merz T; Fuller SH
    Am J Health Syst Pharm; 2007 Sep; 64(17):1818-21. PubMed ID: 17724362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
    Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
    Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
    Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
    Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?
    Milionis HJ; Gazi IF; Filippatos TD; Tzovaras V; Chasiotis G; Goudevenos J; Seferiadis K; Elisaf MS
    Angiology; 2005; 56(5):585-92. PubMed ID: 16193198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.
    Moura LM; Ramos SF; Zamorano JL; Barros IM; Azevedo LF; Rocha-Gonçalves F; Rajamannan NM
    J Am Coll Cardiol; 2007 Feb; 49(5):554-61. PubMed ID: 17276178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin in the management of hyperlipidemia.
    Cheng JW
    Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
    Kargiotis K; Katsiki N; Athyros VG; Giouleme O; Patsiaoura K; Katsiki E; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2014 May; 12(3):505-11. PubMed ID: 24805248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.
    Lee SH; Cho KI; Kim JY; Ahn YK; Rha SW; Kim YJ; Choi YS; Choi SW; Jeon DW; Min PK; Choi DJ; Baek SH; Kim KS; Byun YS; Jang Y
    Atherosclerosis; 2012 Mar; 221(1):169-75. PubMed ID: 22269152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study).
    Wiviott SD; Mohanavelu S; Raichlen JS; Cain VA; Nissen SE; Libby P
    Am J Cardiol; 2009 Jul; 104(1):29-35. PubMed ID: 19576317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin resistant dyslipidemia in a patient treated with amiodarone.
    Al-Sarraf A; Li M; Frohlich J
    BMJ Case Rep; 2011 Oct; 2011():. PubMed ID: 22675011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosuvastatin induced rhabdomyolysis in a low risk patient: a case report and review of the literature.
    Khan FY; Ibrahim W
    Curr Clin Pharmacol; 2009 Jan; 4(1):1-3. PubMed ID: 19149497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation.
    Gallelli L; Ferraro M; Spagnuolo V; Rende P; Mauro GF; De Sarro G
    Drug Metabol Drug Interact; 2009; 24(1):83-7. PubMed ID: 19354002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Hsia J; MacFadyen JG; Monyak J; Ridker PM
    J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stain wars.
    Olsson GO; Blasetto JW; Bryzinski BS; Caplan RJ; Gold A
    Lancet; 2003 Nov; 362(9398):1855-6; discussion 1856. PubMed ID: 14654329
    [No Abstract]   [Full Text] [Related]  

  • 20. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.
    Lorenzoni PJ; Silvado CE; Scola RH; Luvizotto M; Werneck LC
    Arq Neuropsiquiatr; 2007 Sep; 65(3B):834-7. PubMed ID: 17952291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.